Literature DB >> 10536650

Serum concentrations of steroids, parathyroid hormone, and calcitonin in postmenopausal women during the year following hip fracture: effect of location of fracture and age.

N H Dubin1, L K Monahan, J A Yu-Yahiro, R H Michael, S I Zimmerman, W Hawkes, J R Hebel, K M Fox, J Magaziner.   

Abstract

BACKGROUND: Hip fracture in the aged is a major health problem, especially considering the increasing proportion of the elderly in the population. This study examines changes in circulating levels of hormones, which are purported to affect bone metabolism, in response to hip fracture in postmenopausal women.
METHODS: Patients consisted of women ages 65 and older who had surgery within 2 days of fracture. Serum samples were obtained at 3, 10, 60, 180, and 360 days postfracture. Healthy women without hip fractures from the same age range served as a control group (n = 17). Hormones were determined by radioimmunoassay. Subjects with fractures in the neck region of the femur (n = 78) were compared to subjects with fractures in the trochanteric region (n = 88).
RESULTS: Estrone concentration (47.6 +/- 5.7 pg/mL; mean +/- SEM) at 3 days postfracture was elevated (p < .001) compared to control levels of 20.7 +/- 4.6 pg/mL. By 2 months, levels had declined to control levels. Androstenedione and the adrenal hormones, DHEAS and cortisol, displayed similar responses. Parathyroid hormone (PTH) levels were not significantly different from the control concentration at 3 days following fracture, but increased (p < .001) during the year following fracture. Calcitonin concentrations were much higher (p < .001) 3 days postfracture (42.1 +/- 3.7 pg/mL) compared to controls without fracture (9.8 +/- 3 pg/mL). Except for testosterone, no differences could be attributed to fracture location. Only PTH, with concentrations higher in the older age groups (p < .001), showed an age-related response.
CONCLUSIONS: Following hip fracture, there are some dramatic responses in hormones that purportedly are mechanistically important in bone metabolism. These changes include transient increases in steroid hormones, chronic elevations in calcitonin, and rising levels of PTH during the year after fracture.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536650     DOI: 10.1093/gerona/54.9.m467

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  5 in total

1.  The hormonal profile of hip fracture female patients differs from community-dwelling peers over a 1-year follow-up period.

Authors:  A R Cappola; W G Hawkes; N Blocher; J Yu-Yahiro; D Orwig; L Fredman; R R Miller; J M Guralnik; J Magaziner
Journal:  Osteoporos Int       Date:  2010-03-04       Impact factor: 4.507

2.  Women with hip fracture have a greater rate of decline in bone mineral density than expected: another significant consequence of a common geriatric problem.

Authors:  J Magaziner; L Wehren; W G Hawkes; D Orwig; J R Hebel; L Fredman; K Stone; S Zimmerman; M C Hochberg
Journal:  Osteoporos Int       Date:  2006-04-07       Impact factor: 4.507

3.  Decrease in serum calcitriol (but not free 25-hydroxyvitamin D) concentration in hip fracture healing.

Authors:  J Vaculik; L Wenchich; M Bobelyak; K Pavelka; J J Stepan
Journal:  J Endocrinol Invest       Date:  2021-01-25       Impact factor: 4.256

4.  Hip fracture risk in relation to vitamin D supplementation and serum 25-hydroxyvitamin D levels: a systematic review and meta-analysis of randomised controlled trials and observational studies.

Authors:  Jeffrey K C Lai; Robyn M Lucas; Mark S Clements; Andrew W Roddam; Emily Banks
Journal:  BMC Public Health       Date:  2010-06-11       Impact factor: 3.295

5.  Depression following hip fracture is associated with increased physical frailty in older adults: the role of the cortisol: dehydroepiandrosterone sulphate ratio.

Authors:  Anna C Phillips; Jane Upton; Niharika Arora Duggal; Douglas Carroll; Janet M Lord
Journal:  BMC Geriatr       Date:  2013-06-17       Impact factor: 3.921

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.